Meda completes acquisition of Valeant western and eastern European businesses
This article was originally published in Scrip
Medahas completed its acquisition of Valeant Pharmaceutical's business in western and eastern Europe for $425 million, after certain closing adjustments raised the amount from the previously announced $392 million. The combined revenue of Valeant's products in western and eastern Europe last year was SEK520 million ($86 million; Scrip Online, August 8th, 2008). Through the acquisition, Meda hopes to enter Russia, as well as create significant market synergies with products in its pipeline.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.